TIMMINS ALAN P 4/A

4/A · CytoDyn Inc. · Filed Nov 30, 2021

Form 4/AAmended

Period: 2021-11-24

Director

Transactions

Disposition to Issuer
Non-qualified Stock Option
2021-11-24−36,986→ 0 total
Exercise: $1.05From: 2020-06-01Exp: 2030-01-18→ Common Stock (36,986 underlying)
Disposition to Issuer
Non-qualified Stock Option
2021-11-24−225,000→ 0 total
Exercise: $6.15Exp: 2030-06-25→ Common Stock (225,000 underlying)
Award
Non-qualified Stock Option
2021-11-24+225,000→ 225,000 total
Exercise: $6.15Exp: 2030-06-25→ Common Stock (225,000 underlying)
Disposition to Issuer
Non-qualified Stock Option
2021-11-24−225,000→ 0 total
Exercise: $1.39Exp: 2031-10-18→ Common Stock (225,000 underlying)
Award
Non-qualified Stock Option
2021-11-24+36,986→ 36,986 total
Exercise: $1.05From: 2020-06-01Exp: 2030-01-18→ Common Stock (36,986 underlying)
Award
Non-qualified Stock Option
2021-11-24+112,500→ 112,500 total
Exercise: $1.39Exp: 2031-10-18→ Common Stock (112,500 underlying)

Footnotes (2)

[F1]The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service.
[F2]56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021.

Documents

1 file